NVO News Explorer

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past six months.Most Read from BloombergHow the 2025 Catholic Jubilee Is Reshaping RomeManhattan’s Morning Commute Time Drops With New Congestion TollTrump Paves the Way to Deputize Local Police on ImmigrationHousing Aid Uncertain After Trump’s Spending Freeze MemoTrump's Federal Funding Pause Th

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

Novo Nordisk announces new early clinical trial data for its latest weight loss drug, amecrytin.

Wall Street stocks are on track for weekly wins as markets ride the Trump roller-coaster.

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

The Biden administration released another list of prescriptions drugs that would be subject to price controls. The price controls for the selected drugs will become effective in 2027.

Investors are appraising Trump policies' likely impact on stocks on the last trading day before the inauguration.

Putting tariffs on Denmark unless it cedes the island of Greenland could hurt access to a few key products, including popular medicines.

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

Novo Nordisk stock sinks on news of its newest GLP-1 candidate.

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

Stocks signaled another rough day of trading on Friday after the House of Representatives voted against a Trump-backed spending bill.

The FDA decided the shortage for Eli Lilly's GLP-1 tirzepatide has finally come to an end.

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear whether Trump's administration will see it through.

There are 180 million people living with obesity in China, who will now be able to purchase the treatment.

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies.

GLP-1 pills are the next frontier for the weight-loss market.

A new study found that weekly injections of 2.4 mg of semaglutide could lower the risk of deaths related to COVID-19, marking another potential benefit of these blockbuster drugs.